[Efficacy and tolerance of ACE inhibitor invoril and angiotensin I At-receptor blocker diovan in patients with stages I-II of arterial hypertension].
A controlled parallel trial was conducted to study an antihypertensive action and tolerance of invoril in a dose of 10-20 mg/day (twice a day) vs diovan in a single dose of 80-160 mg/day in 60 patients (25 men and 35 women) aged under 65 years with arterial hypertension of the first and second degree. Follow-up was 6 weeks. The assessment was made by the data of clinical and biochemical blood tests, ophthalmological examination, registration of ECG and echo-CG. Arterial pressure was measured weekly by a doctor and daily (in the morning and evening) by patients themselves. A complete antihypertensive effect (AP < 150/90 mm Hg) in monotherapy with invoril was achieved in 18 (60%) patients, in therapy with diovan in 26 (86.7%) patients. At the end of the treatment systolic arterial pressure fell in group 1 by 22.6%, diastolic one by 19.2%; in group 2--by 23.4 and 19.7%, respectively. Side effects of invoril treatment occurred in 8 (26.7%) patients, of diovan treatment--in 3 (10%). Thus, invoril and diovan are highly effective and safe drugs for treatment of arterial hypertension of the first and second degree. Antihypertensive effectiveness and tolerance of invoril are inferior to those of diovan.